Lunit Presents AI Innovations in Cancer Care at Major Global Health Summits

Lunit Unveils its AI-Powered Cancer Solutions at Global Health Events

In a powerful demonstration of its commitment to transforming cancer care, Lunit, a prominent name in the field of artificial intelligence (AI) for cancer diagnostics, participated in two major global health gatherings in Seoul, South Korea. These events were the 15th APEC High-Level Meeting on Health and the Economy (HLMHE) and the World Bio Summit 2025 (WBS 2025), both held on September 15-17, 2025.

Lunit was notably the only company from Korea that led a session at the APEC HLMHE, exemplifying its status as a global leader in AI-driven cancer care solutions. The dedicated session on September 16 attracted over 300 influential policymakers, healthcare leaders, and industry experts, all eager to learn about advancements in cancer treatment facilitated by technology.

During this session, Lunit's CEO, Brandon Suh, along with other senior executives and research leaders, outlined several key points illustrating AI's transformative role in cancer screening and treatment across APEC member countries. These points included:
1. Korea's AI Leadership: The approval of government reimbursement for AI technologies has catalyzed large-scale adoptions in over 7,000 medical institutions worldwide, providing support for concrete implementation.
2. Global Case Studies: A showcase of how AI has enabled effective cancer screening methodologies in regions like Southeast Asia, Australia, and Singapore, promoting equitable access to healthcare services while also enhancing cost efficiency.
3. Future Vision: Discussions on advancing multimodal AI approaches that integrate imaging, genomics, and clinical data to push for precision medicine. This includes proposals for cross-border training and shared data infrastructures among APEC nations, aiming to foster collaborative efforts in cancer care advancements.

The efforts of Lunit did not stop at the APEC event. On September 17, CEO Brandon Suh is set to moderate the WBS 2025 Leaders' Dialogue, inviting prominent figures such as Dr. Philippe Duneton, the Executive Director of Unitaid, to join discussions on the future landscape of healthcare.

In addition to its speaking engagements, Lunit showcased its cutting-edge AI solutions at an on-site booth throughout both events, enabling attendees to witness live demonstrations of their flagship products in cancer screening and AI pathology.

Brandon Suh emphasized, "AI is no longer a mere concept for the future; it is already having a significant impact on patients and healthcare systems today. Our collaboration with governments, global organizations, and research institutions is critical in ensuring that advancements in AI-powered cancer care reach every part of the globe."

Established in 2013, Lunit has focused on delivering pioneering AI solutions aimed at revolutionizing cancer diagnostics and therapeutics. The company’s Lunit INSIGHT suite of AI tools has gained FDA clearance and is currently utilized in over 7,000 healthcare institutions across 65 countries. Moreover, Lunit SCOPE, which collaborates with pharmaceutical giants for biomarker development, further reinforces the company’s leadership in this domain.

Lunit's clinical research has been published in esteemed journals, including The Lancet Digital Health and the Journal of Clinical Oncology, and presented at prestigious conferences such as ASCO and RSNA. With headquarters in Seoul and branches worldwide, Lunit continues to be at the forefront of the global fight against cancer, committed to its mission of leveraging AI to conquer this devastating disease.

For more information on Lunit and its innovative approaches to cancer care, visit lunit.io.